Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.
Clinical Trials Arena on MSN
ASH 2025: Cullinan’s T-cell engager boasts potential across p53 AML subset
CLN-049’s anti-leukaemic impact was observed regardless of FLT3 status, which is the most commonly mutated protein in AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback